Small molecule · Inhibitor of Aurora kinase A (AURKA), Aurora kinase B (AURKB) and Aurora kinase C (AURKC)
Phase 1Most advanced trial (none active)
1Registered trials
What is TTP607?
TTP607 is a small-molecule pan-Aurora kinase inhibitor that binds and inhibits Aurora kinases A, B and C, serine/threonine kinases essential for mitotic checkpoint control. It is being studied in advanced cancers and lymphoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Small molecule
Targets
Aurora kinase A (AURKA), Aurora kinase B (AURKB), Aurora kinase C (AURKC)
Mechanism
Inhibitor of Aurora kinase A (AURKA), Aurora kinase B (AURKB) and Aurora kinase C (AURKC)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.